Prevention of Syncope Trial 6 - Atomoxetine in Vasovagal Syncope

• Status: Completed
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Objective: To determine if atomoxetine 40 mg bid (bis in die) in patients ≥18 years old with recurrent vasovagal syncope will better prevent syncope during tilt testing than placebo.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Calgary
• Collaborator: Cardiac Arrhythmia Network of Canada
• Treatments: Atomoxetine Hydrochloride

Criteria

Inclusion Criteria:

• 1 or more syncopal spells in the year preceding enrolment

• More than -2 points on the Calgary Syncope Symptom Score

• Age ≥18 years with informed consent

Exclusion Criteria:

• Other causes of syncope, such as ventricular tachycardia, complete heart block, orthostatic hypotension or hypersensitive carotid sinus syndrome

• Inability to give informed consent

• important valvular, coronary, myocardial or conduction abnormality or significant arrhythmia.

• hypertrophic cardiomyopathy

• a permanent pacemaker

• a seizure disorder

• hypertension defined as >150/90 mm Hg

• pregnancy

• glaucoma

• medications with known effects on blood pressure

• Known hypersensitivity to atomoxetine and derivatives